Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice

Diabetes worsens atherosclerosis progression and leads to a defect in repair of arteries after cholesterol reduction, a process termed regression. Empagliflozin reduces blood glucose levels via inhibition of the sodium glucose cotransporter 2 (SGLT-2) in the kidney and has been shown to lead to a ma...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Sci Rep
Huvudupphovsmän: Pennig, Jan, Scherrer, Philipp, Gissler, Mark Colin, Anto-Michel, Nathaly, Hoppe, Natalie, Füner, Lisa, Härdtner, Carmen, Stachon, Peter, Wolf, Dennis, Hilgendorf, Ingo, Mullick, Adam, Bode, Christoph, Zirlik, Andreas, Goldberg, Ira J., Willecke, Florian
Materialtyp: Artigo
Språk:Inglês
Publicerad: Nature Publishing Group UK 2019
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6884628/
https://ncbi.nlm.nih.gov/pubmed/31784656
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-54224-9
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk